by B2i | Jul 30, 2020 | Press Releases
JUPITER, FL / July 30, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve...
by B2i | Jul 15, 2020 | Press Releases
JUPITER, FL / July 15, 2020 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary...
by B2i | Jul 8, 2020 | Press Releases
Dyadic Now Partnered with all of the Top Four Animal Health Companies Five Fully Funded Animal Health Research Projects with Three New Relationships Announced this Year JUPITER, FL / July 8, 2020 / Dyadic International, Inc. (“Dyadic”, “we”,...
by B2i | Jun 29, 2020 | Press Releases
JUPITER, FL / June 29, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and...
by B2i | Jun 10, 2020 | Press Releases
JUPITER, FL / June 10, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development,...
by B2i | May 14, 2020 | Press Releases
Two fully funded research projects with top four animal health companies. Nonexclusive research license agreement with WuXi Biologics. Feasibility study with the University of Oslo on influenza vaccine. Engineered C1 cell lines to produce high levels of potential...
